

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM860406

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
BMO Bank N.A.	FORMERLY BMO Harris Bank N.A.	12/12/2023	National Banking Association: UNITED STATES
RECEIVING PARTY DATA			
Name:	Worldwide Clinical Trials, Inc.		
Street Address:	600 Park Offices Drive		
Internal Address:	Suite 200		
City:	Research Triangle Park		
State/Country:	NORTH CAROLINA		
Postal Code:	27708		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 3			
Property Type	Number	Word Mark	
Registration Number:	3619881	WCT	
Registration Number:	3521264	WORLDWIDE CLINICAL TRIALS	
Registration Number:	4060750	WCT RESOURCING SOLUTIONS	
CORRESPONDENCE DATA			
Fax Number:			
	<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Phone:	14155911000		
Email:	TrademarksCH@winston.com		
Correspondent Name:	Becky L. Troutman, Winston & Strawn LLP		
Address Line 1:	101 California Street		
Address Line 4:	San Francisco, CALIFORNIA 94111		
NAME OF SUBMITTER:	Becky L. Troutman		
SIGNATURE:	/Becky L. Troutman/mp		
DATE SIGNED:	12/12/2023		
Total Attachments: 4			
source=BMO_WCT - Termination and Release of IP Security Interest (Executed)#page1.tif			
source=BMO_WCT - Termination and Release of IP Security Interest (Executed)#page2.tif			

CH \$90.00 3619881

source=BMO_WCT - Termination and Release of IP Security Interest (Executed)#page3.tif

source=BMO_WCT - Termination and Release of IP Security Interest (Executed)#page4.tif

TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT

This **TERMINATION AND RELEASE OF INTELLECTUAL PROPERTY SECURITY AGREEMENT**, dated as of December 12, 2023 (this “Release”), is made by BMO BANK N.A. (formerly known as BMO HARRIS BANK N.A.), as collateral agent for the Secured Parties (in such capacity, the “Administrative Agent”) in favor of WORLDWIDE CLINICAL TRIALS, INC., a Delaware corporation (the “Grantor”).

WHEREAS, pursuant to that certain Guarantee and Collateral Agreement, dated as of December 5, 2017, made by and among the Grantor and each of the other entities listed as party thereto in favor of the Administrative Agent as collateral agent for the Secured Parties, the Grantor granted to the Administrative Agent for the benefit of the Secured Parties, a security interest (the “Security Interest”) in certain collateral, including the Intellectual Property Collateral.

WHEREAS, as a condition of the Guarantee and Collateral Agreement, the Grantor executed that certain Intellectual Property Security Agreement, dated as of December 5, 2017 (the “IP Security Agreement”), and granted to the Administrative Agent a security interest in all right, title and interest of the Grantor in and to the Intellectual Property Collateral, including the Trademarks listed on Schedule I hereto, and the applications and registrations thereof, and all proceeds thereof, including, without limitation, any and all causes of action which may exist by reason of infringement thereof and any and all damages arising from past, present and future violations thereof;.

WHEREAS, the IP Security Agreement was recorded at the United States Patent and Trademark Office (“USPTO”) at Reel 6224 Frame 0594 on December 8, 2017 for the Trademarks.

WHEREAS, the Grantor has satisfied the terms of the IP Security Agreement and requests a specific release of the security interest granted and recorded against its Intellectual Property Collateral.

NOW THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Administrative Agent hereby agrees as follows:

SECTION 1. Defined Terms. All capitalized terms used herein but not otherwise defined herein have the meanings given to them in the Guarantee and Collateral Agreement and IP Security Agreement.

SECTION 2. Termination and Release. The Administrative Agent hereby:

(a) terminates the IP Security Agreement and terminates, cancels, discharges, and releases all of its security interests in and to all right, title and interest of the Grantor in and to all Intellectual Property Collateral, whether granted pursuant to the IP Security Agreement or otherwise (and including, but not limited to, the Trademarks listed on Schedule I attached hereto);

(b) reassigns and transfers to the Grantor all of its right, title and interest in and to all Intellectual Property Collateral, whether granted pursuant to the IP Security Agreement or otherwise (including, but not limited to the Trademarks listed on Schedule I attached hereto);

(c) authorizes the Grantor or any of their authorized representatives to file this Release with the USPTO or any similar office or agency within or outside the United States at the Grantor’s expense;

(d) further authorizes and requests that the Commissioner for Patents or Trademarks and any other applicable government officer record this Release; and

(e) agrees to execute, acknowledge, procure, and deliver any further documents and to do such other acts as may be reasonably requested by the Grantor, at the Grantor's expense, to fully effectuate the purposes of this Release.

SECTION 4. Choice of Law. This Release shall be governed by and construed in accordance with the laws of the State of New York.

[Signature page follows]

IN WITNESS WHEREOF, the Administrative Agent has caused this Termination and Release of Intellectual Property Security Interest to be duly executed as of the date first set forth above.

ADMINISTRATIVE AGENT:

BMO BANK N.A., as Administrative Agent

By: Matt Lynch
Name: Matt Lynch
Title: Vice President

Schedule I

Trademark	Status	App. #	Filing Date	Reg. #	Reg. Date	Owner
WCT	Dead	77/135153	03/20/2007	3619881	05/12/2009	Worldwide Clinical Trials, Inc.
WORLDWIDE CLINICAL TRIALS and Design	Registered	77/070676	12/22/2006	3521264	10/21/2008	Worldwide Clinical Trials, Inc.
WCT RESOURCING SOLUTIONS	Dead	77/790207	03/22/2010	4060750	11/22/2011	Worldwide Clinical Trials US, Inc.